Literature DB >> 9247832

Evidence of interhospital transmission of extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in the United States, 1986 to 1993. The National Nosocomial Infections Surveillance System.

D L Monnet1, J W Biddle, J R Edwards, D H Culver, J S Tolson, W J Martone, F C Tenover, R P Gaynes.   

Abstract

BACKGROUND: In addition to single-hospital outbreaks, interhospital transmission of extended-spectrum beta-lactam-resistant (ESBLR) Klebsiella pneumoniae has been suspected in some reports. However, these studies lacked sufficient epidemiological information to confirm such an occurrence.
METHODS: We reviewed the surveillance data reported to the National Nosocomial Infections Surveillance (NNIS) System during 1986 to 1993 for K pneumoniae isolates and their susceptibility to either ceftazidime, cefotaxime, ceftriaxone, or aztreonam. Pulsed-field gel electrophoresis (PFGE) was used to study available ESBLR K pneumoniae isolates.
RESULTS: Among 8,319 K pneumoniae isolates associated with nosocomial infections, 727 (8.7%) were resistant or had intermediate-level resistance to at least one of these antibiotics. One hospital (hospital A) accounted for 321 isolates (44.2%) of ESBLR K pneumoniae. During 1986 to 1993, the percentage of K pneumoniae isolates that were ESBLR increased from 0 to 57.7% in hospital A, from 0 to 35.6% in NNIS hospitals 0 to 20 miles from hospital A (area B), and from 1.6 to 7.3% in NNIS hospitals more than 20 miles from hospital A, including hospitals located throughout the United States. Analysis of PFGE restriction profiles showed a genetic relationship between a cluster of isolates from hospital A and some isolates from one hospital in area B, and consecutive admission in these two hospitals was confirmed for two patients from whom isolates were available.
CONCLUSIONS: These data provide evidence of interhospital transmission of ESBLR K pneumoniae in one region of the United States and stress the interrelationship between hospitals when trying to control antimicrobial resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247832     DOI: 10.1086/647654

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  7 in total

1.  Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strains causing nosocomial outbreaks of infection in the United Kingdom.

Authors:  K Shannon; P Stapleton; X Xiang; A Johnson; H Beattie; F El Bakri; B Cookson; G French
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

2.  Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates.

Authors:  Laure Diancourt; Virginie Passet; Jan Verhoef; Patrick A D Grimont; Sylvain Brisse
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut.

Authors:  F C Tenover; M J Mohammed; T S Gorton; Z F Dembek
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

4.  Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Authors:  D F Sahm; I A Critchley; L J Kelly; J A Karlowsky; D C Mayfield; C Thornsberry; Y R Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 5.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

6.  Molecular serotyping of Klebsiella species isolates by restriction of the amplified capsular antigen gene cluster.

Authors:  Sylvain Brisse; Sylvie Issenhuth-Jeanjean; Patrick A D Grimont
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

7.  Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals.

Authors:  Scott K Fridkin; Holly A Hill; Nataliya V Volkova; Jonathan R Edwards; Rachel M Lawton; Robert P Gaynes; John E McGowan
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.